Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. And investors become more bullish about its long-term prospects,
Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford and Chief of the Division of Pain Medicine at the university. Dr. Mackey, welcome to Science Friday.
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a growing number of alternative approaches. Their ultimate uptake, however, remains to be seen.
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of
Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 5.86% on an annualized basis producing an average annual return of 17.7%. Currently, Vertex Pharmaceuticals has a market capitalization of $123.81 billion.
Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly available—through private and public payer coverage—but also easy for doctors to deploy in the clinic.
Vertex Pharmaceuticals (NASDAQ ... the company can now add to its list of approved drugs. On Jan. 30, the FDA granted approval for Vertex's pain medication, Journavx. It's a non-opioid treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results